What is the recommended dose of dexamethasone (Decadron) for the Dexamethasone Suppression Test (DST)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dexamethasone Dosing for DST

For the overnight 1-mg dexamethasone suppression test (DST), administer 1 mg orally between 11:00 PM and midnight, with serum cortisol measured at 8:00 AM the following morning. 1

Overnight 1-mg DST Protocol

  • Administer 1 mg dexamethasone orally between 11:00 PM and midnight 1
  • Measure serum cortisol at 8:00 AM the following morning 1
  • Normal response is defined as serum cortisol < 1.8 μg/dL (50 nmol/L), which has >90% sensitivity for detecting Cushing's syndrome 1
  • Serum cortisol > 5.0 μg/dL (138 nmol/L) suggests autonomous cortisol secretion 1

2-Day Low-Dose DST (LDDST) Protocol

For the 2-day LDDST, administer 0.5 mg dexamethasone orally every 6 hours (at 09:00,15:00,21:00, and 03:00) for 48 hours. 2

  • Measure cortisol at 0,24, and 48 hours 2
  • Normal response is cortisol suppression to < 1.8 μg/dL (50 nmol/L), which effectively rules out Cushing's syndrome 2
  • This test has 95% sensitivity and 80% specificity when using the ≥50 nmol/L cutoff as diagnostic for Cushing's syndrome 2

Critical Considerations for Test Accuracy

Measure serum dexamethasone levels concomitantly with cortisol to reduce false-positive results caused by inadequate dexamethasone bioavailability or noncompliance. 1, 3

  • A dexamethasone threshold of ≥4.5 nmol/L indicates adequate bioavailability after the 1-mg overnight test 4
  • Approximately 6% of non-Cushing's patients fail to achieve adequate dexamethasone levels, accounting for 40% of false-positive results (cortisol >138 nmol/L) 4
  • Measuring dexamethasone reduces the false-positive rate by identifying the 14% of patients with unsuppressed cortisol due to subtherapeutic dexamethasone levels 3

Common Pitfalls and Drug Interactions

CYP3A4 inducers cause false-positive results by accelerating dexamethasone metabolism, while CYP3A4 inhibitors cause false-negative results. 2, 1

  • False-positive causes (failure to suppress despite no Cushing's): phenobarbital, carbamazepine, St. John's wort, rifampin 2, 1
  • False-negative causes (suppression despite Cushing's): fluoxetine, cimetidine, diltiazem 2, 1
  • Malabsorption or rapid gut transit can also cause false-positive results 1

Important Diagnostic Nuances

The 1-mg overnight DST has high sensitivity (>90%) but moderate specificity (63% at 50 nmol/L cutoff, increasing to 91% at 138 nmol/L cutoff). 4

  • Research demonstrates that 18% of patients with proven Cushing's disease suppress cortisol to <5 μg/dL, and 8% suppress to <2 μg/dL after the 1-mg test, highlighting that low-dose DST should not be used as the sole criterion to exclude Cushing's syndrome 5
  • The 2-day LDDST yields false-negative results in 38% of patients when using urine cortisol and 28% when using urinary 17-hydroxycorticosteroids 5
  • Pseudo-Cushing's states (depression, alcoholism, obesity) can produce false-positive results 1

Alternative Dosing Considerations

Dexamethasone timing can be adjusted from 23:00 to 21:00 without affecting cortisol suppression in healthy subjects. 6

  • The 0.5 mg dose suppresses cortisol to a similar extent as 1.0 mg in healthy subjects, while 0.25 mg provides less suppression 6
  • However, the standard 1-mg dose at 11:00 PM-midnight remains the guideline-recommended protocol 1

References

Guideline

Dexamethasone Suppression Test Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Interpretation of 2-Day LDDST Results

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The low-dose dexamethasone suppression test: a reevaluation in patients with Cushing's syndrome.

The Journal of clinical endocrinology and metabolism, 2004

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.